24 results about "Annexin" patented technology

The current invention relates to a composition comprising extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs). The EVs are part of a population of particles in the composition having a particle size of between 0.05 and 0.22 micron. The concentration of these particles is at least 1×1011 particles per ml of composition. At least 90% of the particles with particle size of between 0.05 and 0.22 micron are EVs. The EVs are defined by having a concentration of intra-vesicular Annexin V of at least 40 ng / ml and a concentration of extra-vesicular Annexin V of less than 1 ng / ml. Uses of the composition also are disclosed.

The present invention provides synthetic polypeptides comprising an annexin V protein, or a functional portion or fragment or variant thereof, conjugated to a tumor antigen, or a functional portion or fragment or variant thereof. The invention further provides methods for making said synthetic polypeptides and their use in the treatment of proliferative diseases such as cancer and tumors originating therefrom.

This invention belongs to the fields of medicinal chemistry and pharmaceutical technology, and relates to 1,4-benzodiazepines and their use in the preparation of antitumor drugs, specifically the use of 1,4-benzodiazepines in the preparation of annexin A3 (ANXA3) degrading agents and in the preparation of drugs for treating cancer. In particular, it discloses the use of 1,4-benzodiazepines, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or compositions of drugs with these as active ingredients, in the preparation of drugs for the prevention and treatment of tumors. These compounds can bind to the ANXA3 protein, induce ANXA3 protein degradation, inhibit the proliferation, cloning, migration, and invasion of tumor cells, and exert antitumor therapeutic effects in vivo. They can be used to treat solid tumors and hematological malignancies, including breast cancer, cervical cancer, ovarian cancer, colorectal cancer, gastric cancer, pancreatic cancer, lung cancer, esophageal cancer, liver cancer, leukemia, and melanoma.

The present invention refers to Annexin A8 (AnxA8) inhibitors, or pharmaceutical composition comprising thereof, for use in a method for the treatment and / or prevention of atherosclerosis. Preferably, the method comprises preventing atherosclerotic plaque formation.

Methods are provided for treating a subject with cancer, with a therapeutic dose of annexin V to the subject.

The invention belongs to the technical field of biological detection, and particularly relates to application of annexin A3 (ANXA3) in detection of critical illness death early warning and sepsis diagnosis. It is found that the ANXA3 protein amount in plasma of a critically ill patient is remarkably higher than that in a healthy voluntary person, the ANXA3 protein amount in plasma of a critically ill sepsis patient is remarkably higher than that in plasma of a critically ill non-sepsis patient, and the ANXA3 protein amount in the plasma is further remarkably related to the death risk of the critically ill patient. By detecting the blood plasma ANXA3 protein amount, sepsis occurrence and death risks of critically ill patients can be evaluated, individualized treatment can be started as soon as possible, and the kit has important clinical application value for prognosis of critically ill patients.

The invention discloses a method for accurately determining the motility rate of MSC cells, and belongs to the technical field of motility rate detection of mesenchymal stem cells (MSC). The method mainly comprises the following steps: S1, taking out cryopreserved cells from liquid nitrogen, placing the cryopreserved cells in dry ice, transferring the cryopreserved cells to a laboratory, and carrying out unfreezing resuscitation in a 37 DEG C water bath; s2, taking recovered cells (3E6Cell), averagely transferring the recovered cells (3E6Cell) into three 1.5 ml EP tubes (1E6Cell / tube), adding 1ml of LDPBS, carrying out centrifugation for 5 min, discarding the supernatant, repeating the step once, and then carrying out resuspension by using 100 [mu] l of DPBS for later use; s3, dye preparation: taking one EP tube, adding 400 [mu] l of Annexin V Loading buffer, 10 [mu] l of Annexin V and 10 [mu] l of 7AAD into the EP tube, and carrying out vortex uniform mixing for later use; s4, dyeing: adding 100 microliters of prepared dye into 100 microliters of prepared sample, lightly and uniformly mixing, and incubating in a dark place for 10 minutes; s5, after the dyeing is finished, adding 100 [mu] l of Annexin V loading buffer into each tube, uniformly mixing, and carrying out on-machine detection on a flow cytometer; and S6, taking the average value of the three times of detection data for reporting. The method for accurately determining the cell viability of the MSC achieves the effect of reliable cell counting.

The present disclosure provides immunogenic compositions, such as vaccines, including DNA vaccines, and uses thereof, for example, including annexin core domains for mediating effective antigen delivery and antigen presentation to induce antigen-specific immune responses, and / or to treat or prevent infectious diseases and / or cancer.

The invention relates to the technical field of drug dose screening, in particular to a method for screening the optimal dose of metformin for treating vascular dementia by using an OGD / R-SHSY5Y cell model, which comprises the following steps: constructing the OGD / R-SHSY5Y cell model to simulate the pathological state of vascular dementia; setting a control group, an OGD / R model group and a metformin treatment group with different concentrations, and additionally arranging a pathway inhibitor verification group; the cell proliferation activity is detected through a CCK8 method, the cell apoptosis rate is detected through an Annexin-V-FITC / PI double staining method, expression of apoptosis-related genes and key genes is detected through a qPCR method and a Western blot method, and the inflammatory factor level is detected through an ELISA method. By integrating multi-dimensional detection results, the optimal dosage of the metformin, which not only can significantly improve cell viability and inhibit cell apoptosis, but also can effectively regulate and control key gene expression and inflammatory factor balance, is screened out. Through multi-index collaborative detection and pathway mechanism verification, accurate screening of the optimal dose of the metformin for treating vascular dementia is realized.

The invention discloses an application of a transporter-derived annexin A6 as a breast cancer diagnostic marker, which comprises the following steps: screening annexin A6 (ANXA6) as a candidate marker from transporters derived from different molecular typing breast cancer cells through protein spectrum analysis, and separating the transporter from serum through density gradient centrifugation. And detecting the content of the migration body ANXA6 in the serum sample by adopting an ELISA method. ROC curve analysis shows that the AUC value of the serum transporter ANXA6 for diagnosing breast cancer is 0.959, the sensitivity is 93.8%, and the specificity is 85.3%. Compared with the prior art, the serum migration body serves as a novel detection carrier of ANXA6 for the first time, and the problems that an existing detection mode is high in tissue sample invasiveness, dynamic monitoring cannot be achieved, exosome heterogeneity is high, and the signal-to-noise ratio is low are solved.

This invention relates to a method for preparing annexin-coated phospholipid carriers and its application. The preparation method includes adding annexin and a phospholipid carrier to a buffer solution, mixing and incubating, and then preparing the carrier. The incubation temperature is 4℃-37℃, and the time is 1-10 min. This invention achieves rapid coating of annexin at a suitable temperature and within a short time, solving problems such as decreased protein activity, damage to the physicochemical properties of nanocarriers, and difficulty in rapid on-site application of formulations caused by high-temperature and long-term incubation in traditional preparation processes.

The invention discloses a pharmaceutical composition for targeted removal of osteoarthritis articular cavity apoptotic cells and application, and belongs to the technical field of biological medicines. The pharmaceutical composition comprises a targeting ligand, an apoptotic cell scavenger and a drug carrier, the targeting ligand is selected from an anti-phosphatidylserine monoclonal antibody or Annexin V protein, and can be specifically combined with phosphatidylserine on the surface of an apoptotic cell; the apoptotic cell scavenger is selected from demethoxycurcumin, andrographolide and the like, and can promote apoptotic cell phagocytosis and inhibit inflammatory factor release; and the drug carrier is hyaluronic acid-polylactic acid copolymer nanoparticles, and has good articular cavity retention property and drug sustained release effect. The pharmaceutical composition disclosed by the invention can be used for accurately targeting apoptotic cells in osteoarthritis articular cavities, efficiently removing the apoptotic cells, inhibiting inflammatory response and delaying cartilage degeneration, is good in biological safety and provides a new effective means for treating osteoarthritis.

The invention discloses application of miR-29a-3p in targeting PLSCR4 and inhibiting vascular inflammation and an evaluation method of miR-29a-3p, and relates to the technical field of biomedicine.The method comprises the following steps that miR-29a-3p simulant or inhibitor is transfected to human umbilical vein endothelial cells and then stimulated with TNF-alpha, inflammatory response is evaluated through qRT-PCR, Western blot, immunofluorescence, Transwell migration, mononuclear cell chemotaxis and scanning electron microscope technologies, and therefore the inflammatory response is evaluated. According to the present invention, the PLSCR4 is identified as the miR-29a-3p direct target through the dual luciferase reporter gene experiment, the overexpression or knockout effect of the PLSCR4 is evaluated through Annexin V-PI dyeing and flow cytometry, the in vivo model of the mouse is established, the intravenous injection of the miR-29a-3p agonist is performed, and the lung tissue inflammation is analyzed by using the immunohistochemical method; the invention discloses that miR-29a-3p inhibits the activation of NLRP3 inflammasomes by down-regulating PLSCR4, so that the CASP1 mediated GSDMD cutting and subsequent cell pyroptosis pore formation are inhibited.

The present invention relates to a medicament for treating lung injury, in particular, the present invention provides the use of a Annexin for the manufacture of a composition or formulation for one or more uses selected from the group consisting of: (i) preventing and / or treating lung injury; (ii) reducing the number of neutrophils.

The invention discloses an HIT functional detection method and device, a storage medium and a medical experiment diagnosis platform, and the method comprises the following steps: preparing standard platelet-rich plasma and platelet-deficient plasma to be detected, and preparing heparin working solutions with different concentrations; a reaction system is built according to the standard platelet-rich plasma, the platelet-deficient plasma to be detected and the heparin working solutions with different concentrations, and the reaction system comprises a heparin-free group, a low-heparin-concentration group and a high-heparin-concentration group; respectively adding a fluorescently labeled CD41 / CD61 antibody, a fluorescently labeled CD62P antibody and Annexin V into the heparin-free group, the low-heparin-concentration group and the high-heparin-concentration group, and obtaining procoagulant platelet proportions corresponding to the heparin-free group, the low-heparin-concentration group and the high-heparin-concentration group through flow cytometry; and generating an HIT detection result according to the procoagulant platelet proportions corresponding to the heparin-free group, the low-heparin-concentration group and the high-heparin-concentration group and a preset proportion threshold. Therefore, radioactive substance application is avoided, the operation process is simple and convenient, the detection precision is high, and clinical application is facilitated.

In the body, adipose tissue is comprised of adipocytes as well as various other cell types, including immune cells, that may contribute to the overall extracellular vesicle pool. Adiponectin, a protein hormone produced by fat cells, and fatty acid binding protein 4 (FABP4) were selected as markers to isolate adipocyte- specific EVs / adipomes from the total pool of white adipose tissue-derived EVs based on in vitro data showing that they colocalized with Annexin V, an apoptosis marker, on the surface of budding apoptotic bodies. Intact L-adipomes (large- adipomes) and S-adipomes (small-adipomes) were successfully and selectively enriched from large-EVs and small-EVs, respectively. Immunoblotting analysis confirmed the presence of adiponectin, FABP4, Annexin V, and perilipin in both L- and S-adipomes, providing further evidence of their adipocyte origin.

The application discloses a probiotic EcN△lpp-A5 strain and a construction method and application thereof, the probiotic EcN△lpp-A5 strain takes the probiotic Escherichia coli Nissle 1917 as a chassis, knocks out the outer membrane lipoprotein gene lpp, introduces a fusion protein formed by annexin V (Annexin V) and an Lpp signal peptide sequence and an OmpA anchoring domain sequence, and expresses the annexin V fusion protein on the surface of bacterial cells. The probiotic EcN△lpp-A5 constructed in the application has the characteristics of genetic stability and no exogenous resistance; the strain retains the original probiotic characteristics of EcN, realizes intestinal target colonization and long-time retention, and has the performance of continuously expressing and secreting exogenous recombinant proteins. The strain has strong intestinal targeting and high colonization ability, is safe, is suitable for oral administration, has a mature preparation process, and is convenient for large-scale production.

The invention relates to a fluorescence detection method of an embryonic stem cell exosome. The method comprises the following steps: capturing the embryonic stem cell exosome by Annexin V functional particles; combining a probe T marked by cholesterol with the embryonic stem cell exosome; then, the CRISPR-Cas12a based on strand displacement is used for mediating cascade signal amplification; and finally detecting in real time. Compared with a common CRISPR / Cas-based biosensing platform, the method disclosed by the invention not only can realize high-sensitivity detection of the embryonic stem cell exosome, but also widens the application scene of the nucleic acid nanoprobe and the CRISPR-Cas system in fluorescent biosensing.

In the body, adipose tissue is comprised of adipocytes as well as various other cell types, including immune cells, that may contribute to the overall extracellular vesicle pool. Adiponectin, a protein hormone produced by fat cells, and fatty acid binding protein 4 (FABP4) were selected as markers to isolate adipocyte-specific EVs / adipomes from the total pool of white adipose tissue-derived EVs based on in vitro data showing that they colocalized with Annexin V, an apoptosis marker, on the surface of budding apoptotic bodies. Intact L-adipomes (large-adipomes) and S-adipomes (small-adipomes) were successfully and selectively enriched from large-EVs and small-EVs, respectively. Immunoblotting analysis confirmed the presence of adiponectin, FABP4, Annexin V, and perilipin in both L- and S-adipomes, providing further evidence of their adipocyte origin.

The current invention relates to isolated Extracellular Vesicles (EVs) or a pharmaceutical composition comprising an effective amount of said EVs for use in the treatment of an ocular surface disease, wherein said EVs are administered to the eye of a patient suffering from said ocular surface disease, wherein said EVs are MSC (Mesenchymal Stem Cells) derived EVs, preferably umbilical cord MSC-derived EVs, 10 wherein said EVs are associated with albumin and Annexin V, and wherein said EVs are positive for CD44 and CD29.

The invention discloses a probiotic EcN lpp-A5-alpha TN strain as well as a construction method and application thereof, Escherichia coli Nissle 1917 is taken as a chassis, CRISPR (clustered regularly interspaced short palindromic repeats) is used for knocking out an outer membrane lipoprotein gene lpp, and an Lpp-OmpA-Annexin V fusion protein expression cassette is integrated in situ, so that the probiotic EcN lpp-A5-alpha TN strain which is stable in heredity and free of exogenous resistance is obtained. The strain retains the beneficial characteristics of EcN, and meanwhile, realizes targeted colonization, long-time retention and continuous secretion of anti-TNF-alpha nano antibody alpha TN in intestinal tracts, inhibits immune cell infiltration and rebuilds the immune microenvironment of the intestinal tracts. Animal experiments prove that the traditional Chinese medicine composition has a remarkable curative effect on acute and chronic ulcerative colitis, can be used in combination with 5-aminosalicylic acid, glucocorticoid or a biological preparation, and is safe to orally take, mature in process, low in cost and suitable for large-scale production.

To provide biomarkers for diagnosing desquamative interstitial pneumonia and methods using them. [Solution] A biomarker for determining exfoliative interstitial pneumonia, containing an anti-annexin A autoantibody.

The invention relates to application of an annexin A11 inhibitor in preparation of drugs for improving or treating inflammatory diseases. According to the invention, the annexin A11 is disclosed as a key medium of cfDNA endocytosis, and the important effect of the annexin A11-cyclic guanylate-adenylate synthase protein interaction in activation of inflammation-related pathways is clarified, so that a new target is provided for treatment of inflammatory diseases. The invention also establishes a set of complete method from target discovery to drug verification, so that new candidate drugs can be provided for clinical treatment of inflammatory diseases, and the method has important conversion value. According to the invention, a small molecule drug which can specifically inhibit the interaction of annexin A11-cyclic guanylate-adenylate synthetase and has good biological safety is screened, and meanwhile, the cross-disease treatment potential and obvious curative effect of the drug are verified by using various inflammation models.